Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 50.47 0.36% 0.18
PTLA closed up 0.36 percent on Thursday, October 19, 2017, on 65 percent of normal volume. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Nov 6

Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical PTLA trend table...

Date Alert Name Type % Chg
Oct 19 Hammer Candlestick Bullish 0.00%
Oct 19 Stochastic Buy Signal Bullish 0.00%
Oct 19 Lower Bollinger Band Walk Other 0.00%
Oct 18 Lower Bollinger Band Walk Other 0.36%
Oct 17 Bollinger Band Squeeze Range Contraction -0.06%

Older signals for PTLA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company's products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Is PTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 67.1
52 Week Low 15.68
Average Volume 1,023,905
200-Day Moving Average 44.4586
50-Day Moving Average 55.257
20-Day Moving Average 53.22
10-Day Moving Average 52.648
Average True Range 1.8855
ADX 21.48
+DI 12.12
-DI 27.83
Chandelier Exit (Long, 3 ATRs ) 50.2135
Chandelier Exit (Short, 3 ATRs ) 55.0165
Upper Bollinger Band 56.4298
Lower Bollinger Band 50.0102
Percent B (%b) 0.07
BandWidth 12.062383
MACD Line -1.3223
MACD Signal Line -1.0223
MACD Histogram -0.3
Fundamentals Value
Market Cap 2.91 Billion
Num Shares 57.6 Million
EPS -4.55
Price-to-Earnings (P/E) Ratio -11.09
Price-to-Sales 97.19
Price-to-Book 27.91
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 52.15
Resistance 3 (R3) 51.97 51.22 51.87
Resistance 2 (R2) 51.22 50.80 51.32 51.78
Resistance 1 (R1) 50.85 50.53 51.04 51.03 51.68
Pivot Point 50.10 50.10 50.20 50.20 50.10
Support 1 (S1) 49.73 49.68 49.92 49.91 49.26
Support 2 (S2) 48.98 49.41 49.08 49.16
Support 3 (S3) 48.61 48.98 49.07
Support 4 (S4) 48.79